Hostname: page-component-686fd747b7-hzbls Total loading time: 0 Render date: 2025-02-13T14:02:13.400Z Has data issue: false hasContentIssue false
  • English
  • Français

Co-dergocrine (Hydergine) in the treatment of tardive dyskinesia

Published online by Cambridge University Press:  09 July 2009

Sudhir C. Rastogi ,
Anthony J. Blowers  and
Alan C. Gibson
Sudhir C. Rastogi
Affiliation:
Herrison Hospital, Dorchester, Dorset
Anthony J. Blowers
Affiliation:
Herrison Hospital, Dorchester, Dorset
Alan C. Gibson
Affiliation:
Herrison Hospital, Dorchester, Dorset
Get access Rights & Permissions [Opens in a new window]

Synopsis

In a double-blind, placebo-controlled study with co-dergocrine in the treatment of tardive dyskinesia in a group of elderly chronic psychiatric patients the reduction of dyskinetic scores in the group receiving active medication was slightly greater than that in the placebo group; however, this difference did not reach a level of statistical significance. It is suggested that further work could be undertaken with a longer period of treatment, and at a higher dosage level of co-dergocrine, in a younger patient sample.

Type
Brief Communication
Information
Psychological Medicine , Volume 12 , Issue 2 , May 1982 , pp. 427 - 429
Copyright
Copyright © Cambridge University Press 1982

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Barnes, T. R. E., Kidger, T. & Taylor, P. J. (1978). On the use of dopamine agonists in tardive dyskinesia. American Journal of Psychiatry 135, 132–133.CrossRefGoogle ScholarPubMed
Chien, C. P., Marder, S. R., Van Putten, T. & Escobar, J. (1980). A double-blind study of dihydrogenated ergot alkaloids (Hydergine) in the treatment of tardive dyskinesia. Preliminary report. In 12th Congress of the Collegium Internationale Neuro-Pharmacologicum (CINP), Goteborg (S), 22–26 06 1980 (ed. Hécaen, H.), pp. 105–106. Pergamon Press: Oxford.Google Scholar
Committee on Safety of Medicines (1979). Current Problems No. 4, 04.Google Scholar
Ey, H., Faure, J. & Rappard, P. (1956). Les réactions de tolérance vis à vis de la chlorpromazine. L'Encéphale 45, 790–796.Google Scholar
Goldstein, M., Lew, J. Y., Hata, F. & Lieberman, A. (1978). Binding interactions of ergot alkaloids with monoaminergic receptors in the brain. Gerontology 24, Suppl. 1, 76–85.CrossRefGoogle ScholarPubMed
Gomez, E. (1977). Clinical observations in the treatment of tardive dyskinesia with dihydrogenated ergot alkaloids (Hydergine); preliminary findings. Psychiatric Journal, University of Ottawa 2 (2), 67–71.Google Scholar
Hajioff, J. (1978). Tardive dyskinesia treatment with DEA. British Medical Journal ii, 834.CrossRefGoogle Scholar
Hall, R. A., Jackson, R. B. & Swain, J. M. (1956). Neurotoxic reactions resulting from chlorpromazine administration. Journal of the American Medical Association 161, 214–218.CrossRefGoogle ScholarPubMed
Jeste, D. V. & Wyatt, R. J. (1979). In search of treatment of tardive dyskinesia: review of the literature. Schizophrenia Bulletin 5, 251–293.CrossRefGoogle ScholarPubMed
Loew, D. M., Vigouret, J. M. & Jaton, A. L. (1979). Effects of dihydroergotoxine mesylate (Hydergine) on cerebral synaptic transmission. Interdisciplinary Topics in Gerontology 15, 85–103.CrossRefGoogle Scholar
Mackay, A. V. P., Sheppard, G. P., Saha, B. K., Motley, B., Johnson, A. L. & Marsden, C. D. (1980). Failure of lithium treatment in established tardive dyskinesia. Psychological Medicine 10, 583–587.CrossRefGoogle ScholarPubMed
National Institute of Mental Health, Psychopharmacology Research Branch (1975). Development of a dyskinetic movement scale. Early Clinical Drug Evaluation Unit Intercommunication 4 (1), 3–6.Google Scholar
Nelder, J. A. & Wedderburn, R. W. M. (1972). Generalised linear models. Journal of the Royal Statistical Society, A 135, 370–384.CrossRefGoogle Scholar
Schonecker, M. (1957). Ein eigentümliches Syndrom im oralen Bereich bei megaphen Applikation. Nervenarzt 28, 35–36.Google Scholar
Simpson, G. M., Lee, J. H., Zoubok, B. & Gardos, G. (1979). A rating scale for tardive dyskinesia. Psychopharmacology 64, 171–179.CrossRefGoogle ScholarPubMed
Smith, R. C., Tamminga, C. A., Haraszti, J., Pandey, G. N. & Davis, J. M. (1977). Effects of dopamine agonists in tardive dyskinesia. American Journal of Psychiatry 134, 763–768.Google ScholarPubMed